D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Phase I/II trial of combination nab-paclitaxel and pemetrexed in advanced solid tumor patients (pts) with emphasis on non-small cell lung cancer (NSCLC).
Jonathan W. Riess,Cheryl Ho,Angela M. Davies,Derick H Lau,Primo N. Lara,Helen K. Chew,Laurel A. Beckett,Randeep Sangha,Philip C. Mack,David R. Gandara +9 more
TL;DR: The safety and efficacy of combining nab-paclitaxel (nP) and pemetrexed (P) in solid tumors with a focus on NSCLC for the phase II expansion is evaluated.
Journal ArticleDOI
P3.13-26 Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board
L. Chu,Karen Kelly,David R. Gandara,Primo N. Lara,A. Borowsky,F. Meyers,John Douglas Mcpherson,Rachel L. Erlich,N. Almog,Alexa B. Schrock,S.M. Ali,J.S. Ross,V.A. Miller,Andreas M. Heilmann,Jonathan W. Riess +14 more
Journal ArticleDOI
Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer".
TL;DR: Platinum sensitivity should continue to be considered for clinical practice treatment planning and used as stratification factor in prospective clinical trials of SCLC second-line treatment.
Journal ArticleDOI
NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas.
Zeynep Eroglu,Hussein Tawbi,James C. Hu,Min Guan,Paul Frankel,Nora Ruel,Sharon P. Wilczynski,Scott D Christensen,David R. Gandara,Warren Chow +9 more
TL;DR: A randomized, phase II trial of AZD vs. AZD plus Tem in advanced STS to compare response rate, 4-month PFS rates, and toxicities; and to compare mTOR inhibitors and mTORi possess modest activity against STS.
Journal ArticleDOI
Oral second-line chemotherapy for advanced non-small-cell lung cancer: The bottom line
TL;DR: There appears to be no clear winner among the agents tested in randomized trials of second-line therapy, at least in terms of efficacy parameters, and there are no definitive results to suggest that combinations are superior, although many clinical trials are ongoing investigating the possibilities.